Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now full pipeline small index

Candidemia: full-pipeline trial registry

2 of 9 indexed Candidemia trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 2 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Candidemia: 9 US clinical trials tracked, 2 recruiting.

Candidemia is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Astellas Pharma, running 4 of these trials.

Enrollment posture brief

Registry condition candidemia

OPEN 2 | RECR 22% | LATE 4 | EARLY 4 | RANK #1916 | SPON 4

Nearest open-share peer: Acne (22% recruiting · 27 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Candidemia (this)22%Acute Heart Failure11.1%
Open-enrollment share among volume-matched conditions near Candidemia

Candidemia lists 2 open slots (22% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Candidemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Candidemia is recruiting below its size-band peers.

    2 of 9 indexed trials (22.2%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Candidemia research.

    Astellas Pharma accounts for 4 of 9 trials (44.4%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Candidemia enrolment sits around 450 participants.

    Median target enrolment is 450 among the 9 trials that report a genuine target (sentinel values excluded). 2 of those (22.2%) plan for fewer than 100 participants.

  4. Candidemia research is mostly interventional.

    8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 34

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 3 450 participants

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

Basilea Pharmaceutica

NCT05421858

RECRUITING Phase 2 200 participants

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Radboud University Medical Center

NCT04979052

ACTIVE NOT RECRUITING Phase 3 602 participants

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

Mundipharma Research Limited

NCT04368559

COMPLETED 700 participants

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

T2 Biosystems

NCT01525095

COMPLETED Phase 3 611 participants

Study of Micafungin in Patients With Invasive Candidiasis or Candidemia

Astellas Pharma

NCT00105144

COMPLETED Phase 3 450 participants

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

Astellas Pharma

NCT00413218

COMPLETED Phase 2 207 participants

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

Cidara Therapeutics

NCT02734862

COMPLETED Phase 1 84 participants

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Astellas Pharma

NCT00608335

COMPLETED Phase 1 9 participants

Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

Astellas Pharma

NCT00607763

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 4

Named interventions

Most-linked intervention names on Candidemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Caspofungin Drug
4 trials
Fluconazole Drug
3 trials
Micafungin Drug
2 trials
Micafungin (Mycamine) Drug
1 trials
intravenous placebo Drug
1 trials
CD101 Drug
1 trials
oral placebo Drug
1 trials
Voriconazole Drug
1 trials

US sites by state

Facility locations filed on Candidemia trials. A trial with sites in several states counts in each.

California 8 trials
Alabama 6 trials
Texas 5 trials
Pennsylvania 4 trials
New York 4 trials
North Carolina 4 trials
Missouri 4 trials
Michigan 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Candidemia page

9 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Candidemia condition card totals 9 registered trials; most-linked intervention Caspofungin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.